netFormulary
 Report : Medicines with links to NICE 21/02/2020 22:06:05

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
Abemaciclib 08.01.05 Formulary NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Adalimumab 13.05.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 11.99.99.99 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Afatinib 08.01.05 Formulary NICE TA444: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alpha Tocopheryl Acetate 09.06.05 Formulary NICE NG49: Non-alcoholic fatty liver disease (NAFLD): assessment and management
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anakinra 10.01.03 Restricted Use NICE CG79: Rheumatoid arthritis in adults: management
Anastrozole 08.03.04.01 Formulary NICE CG164: Familial Breast Cancer
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Antithymocyte immunoglobulin (Rabbit) 08.02.02 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Antithymocyte immunoglobulin (Rabbit) 08.02.02 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433: Apremilast for psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Ataluren 10.02 Formulary NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atezolizumab 08.02.03 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.02.03 Formulary NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.02.03 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Avelumab 08.01.05 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.02.04 Formulary NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azithromycin 05.01.05 Formulary NICE evidence summary: Long-term azithromycin for non-CF bronchiectasis
Azithromycin 05.01.05 Formulary NICE Evidence Summary: long-term azithromycin for cystic fibrosis
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belatacept 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Belatacept 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Belimumab 10.01 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA206: Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refractory to rituximab
Bendamustine 08.01.01 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Restricted Use NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 08.01.05 Restricted Use NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan
Bevacizumab 08.01.05 Restricted Use NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Restricted Use NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab 08.01.05 Restricted Use NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.05 Restricted Use NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab 08.01.05 Restricted Use NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Restricted Use NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Restricted Use NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Restricted Use NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Restricted Use NICE TA242: Treatment of metastatic colorectal cancer after first-line chemotherapy
Bevacizumab 08.01.05 Restricted Use NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 08.01.05 Restricted Use NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.05 Restricted Use NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02 Formulary NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Formulary NICE TA253: hepatitis
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Bosutinib 08.01.05 Formulary NICE TA576: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
Botulinum Toxin A 16.01 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Burosumab 10.01.03 Formulary NICE HST8: Burosumab for treating X-linked hypophosphataemia in children and young people
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
Calcium Folinate 08.01 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canakinumab 08.02.04 Non Formulary NICE TA281: Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)
Cangrelor 02.09 Formulary NICE TA351: Reducing Artherothrombotic Events
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE CG81: Advanced breast cancer: diagnosis and treatment
Carboplatin 08.01.05 Non Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Carboplatin 08.01.05 Non Formulary NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Carfilzomib 08.01.05 Formulary NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceftolozane & tazobactam 05.01.02 Formulary NICE 2016: Evidence summary of new medicines: intra-abdominal
Ceftolozane & tazobactam 05.01.02 Formulary NICE 2016: Evidence summary of new medicines: UTI
Cemiplimab 08.02.03 Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Cenegermin 11.08 Non Formulary NICE TA532: Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Cerliponase alpha 16.01 Formulary NICE HST12: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA242: Metastatic colorectal cancer after first-line chemotherapy
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA172: Recurrent and/or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Ciclosporin 11.99.99.99 Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Non Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICT TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Clopidogrel 02.09 Formulary NICE Evidence summary: Clopidogrel for transient ischaemic attack
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colesevelam 02.12 Formulary NICE Evidence Summary: Colesevelam for bile acid malabsorption
Colistimethate Sodium 05.01.07 Formulary NICE Evidence Summary: Non-cystic fibrosis bronchiectasis - colistimethate sodium
Colistimethate Sodium 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
Dabrafenib 08.01.05 Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.04 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Formulary NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Daratumumab 08.01.05 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darbepoetin alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Darvadstrocel 01.05.03 Non Formulary NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
DebriSoft® A5.07 Formulary NICE MTG17: Debrisoft for acute and chronic wounds
Decitabine 08.01.03 Non Formulary NICE TA548: Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA549: Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Formulary NICE CG175: https://www.nice.org.uk/guidance/CG175
Desmopressin 06.05.02 Formulary NICE Evidence Summary: Desmopressin for nocturia in men
Dexamethasone Intravitreal Implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone Intravitreal Implant 11.04.01 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone Intravitreal Implant 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 08.02.04 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dimethyl Sulphoxide Bladder Instillation 50% 07.04.04 Formulary Nice Evidence Summary: Interstitial cystitis - dimethyl sulfoxide bladder instillation
Dinutuximab Beta 08.02.04 Formulary Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Domperidone 04.06 Restricted Use NICE Evidence Summary: Promoting tolerance of enteral feeds in children and young people - domperidone
Donepezil hydrochloride 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dulaglutide 06.01.02.03 Restricted Use NICE Evidence Summary: Dulaglutide for Type 2 diabetes
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01 Formulary NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Formulary NICE evidence summary: eculizumab for prevention of C3 glomerulopathy post-transplant
Eculizumab 09.01.03 Formulary NICE HST1: Eculizumab for atypical haemolytic uraemic syndrome
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir and Grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Formulary NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Erythromycin 05.01.05 Formulary NICE Evidence summary: Erythromycin for gastroparesis in adults
Etanercept 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Exenatide prolonged release 06.01.02.03 Restricted Use NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Fentanyl 04.07.02 Restricted Use NICE Evidence Summary: Moderate to severe acute post-operative pain - fentanyl transdermal patch
Fentanyl 04.07.02 Formulary NICE Evidence Summary: Moderate to severe acute post-operative pain - fentanyl transdermal patch
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms in men: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludrocortisone 06.03.01 Formulary NICE Evidence Summary - Postural hypotension
Fluocinolone Acetonide Intravitreal Implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluocinolone Acetonide Intravitreal Implant 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone Acetonide Intravitreal Implant 11.04.01 Formulary NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
Fluoxetine 04.03.03 Formulary NICE evidence summary: Fluoxetine for hypersexuality
Fosfomycin 3g sachets 05.01.07 Formulary NICE Evidence summary: Fosfomycin for resistant urinary tract infections
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Non Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Galantamine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemcitabine 08.01.03 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Gemtuzumab oxogamicin 08.02.03 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir and Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Glucosamine 10.01.05 Non Formulary NICE Clinical Guidance: Osteoarthritis- care and management
Glycopyrrolate and Indacaterol 03.01.04 Non Formulary NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler)
Glycopyrronium bromide 15.01.03 Formulary NICE: Hypersalivation: oral glycopyrronium bromide
Glycopyrronium Bromide 320 mcg/ml 01.02 Formulary NICE NG31: Care of dying adults in the last days of life
Glycopyrronium Bromide 320 mcg/ml 01.02 Formulary NICE NG42: Motor neurone disease: assessment and management
Glycopyrronium Bromide 320 mcg/ml 01.02 Formulary NICE NG62: Cerebral palsy in under 25s: assessment and management
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Guanfacine 04.04 Formulary NICE Evidence summary: Attention deficit hyperactivity disorder in children and young people
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Holoclar 16.01 Formulary NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
Ibandronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid 06.06.02 Formulary NICE Evidence Summary: Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates
Ibandronic Acid 3mg injection 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid IV infusion 06.06.02 Non Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA608: Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
Idelalisib 08.01.05 Formulary NICE TA604: Idelalisib for treating refractory follicular lymphoma
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Iloprost injection 02.05.01 Formulary NICE: Review of evidence
Imatinib 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Non Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Inositol Nicotinate 02.06.04 Non Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Inotersen 09.08.01 Formulary NICE HST9: Inotersen for treating hereditary transthyretin amyloidosis
Inotuzumab ozogamicin 08.01.05 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Non Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta 08.02.04 Non Formulary NICE TA32: Interferon Beta for MS
Interferon Beta-1a 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1a 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1b 08.02.04 Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1b 08.02.04 Non Formulary NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis
Iodozyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Irinotecan Hydrochloride 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Irinotecan Hydrochloride 08.01.05 Non Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ivermectin 13.10.04 Formulary NICE Evidence Summary: Oral Ivermectin for difficult-to-treat scabies.
Ivermectin cream 13.06 Formulary NICE new medicine summary: Inflammatory lesions of papulopustular rosacea
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 10.01.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 10.01.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lamivudine 05.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lanadelumab 16.01 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA603: Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Formulary NICE TA551:Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letermovir 05.03.02.02 Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Liposomal cytarabine–daunorubicin 08.01.02 Formulary NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Liraglutide 1.2mg 06.01.02.03 Restricted Use NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lutetium (177Lu) oxodotreotide 08.03.04.03 Formulary Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Magnesium Glycerophosphate 4mmol chewable tablets 09.05.01.03 Formulary NICE: Evidence Summary: Oral magnesium glycerophosphate - Preventing recurrent hypomagnesaemia
Mannitol dry powder for inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mefenamic Acid 10.01.01 Formulary CKS Review of Evidence: Drugs to treat menorrhagia
Melatonin 04.01.01 Formulary NICE Evidence summary: Melatonin for sleep disorders in children with ADHD
Memantine hydrochloride 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Metformin Hydrochloride 06.01.02.02 Formulary NICE Evidence Summary: Metformin for PCOS in women who are not planning pregnancy
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Miconazole 12.03.02 Formulary CKS Review of Evidence: Oral candida
Midodrine 02.07.02 Formulary NICE Evidence Summary: Orthostatic hypotension - midodrine
Midostaurin 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Mifepristone 07.01.02 Formulary NICE Evidence summary: Mifepristone for induction of labour in late intrauterine fetal death
Migalastat 09.08.01 Formulary NICE HST4: Migalastat for treating Fabry disease
Minocycline 05.01.03 Formulary NICE therapeutic topic: Minocycline
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Modafinil 04.04 Formulary NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis
Modafinil 04.04 Formulary NICE Evidence Summary: Modafinil for excessive daytime sleepiness in Parkinson’s disease
Mycophenolate Mofetil 08.02.01 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Mycophenolate Mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Mycophenolate Mofetil 08.02.01 Formulary NICE Evidence Summary: Mycophenolate for scleroderma
Mycophenolate Mofetil 08.02.01 Formulary NICE Evidence Summary: Mycophenolate for SLE
Mycophenolate Sodium 08.02.01 Non Formulary NICE Evidence Summary: Mycophenolate for scleroderma
Mycophenolate Sodium 08.02.01 Non Formulary NICE Evidence Summary: Mycophenolate for SLE
Mycophenolate Sodium 08.02.01 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Mycophenolate Sodium 08.02.01 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Naftidrofuryl Oxalate 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Naftidrofuryl Oxalate 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naloxegol 01.06.06 Restricted Use NICE TA345:Naloxegol for treating opioid‑induced constipation
Naltrexone Hydrochloride 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Naltrexone-bupropion 04.05 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Neratinib 08.03.04.01 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Niraparib 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.04 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.02.04 Formulary NICT TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.04 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.04 Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.02.04 Formulary NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nusinersen 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Nystatin 12.03.02 Formulary CKS Review of Evidence: Oral candida
Obeticholic acid 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaparib 08.02.04 Formulary NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Ombitasvir - Paritaprevir - Ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Omega-3-Acid Ethyl Esters 02.12 Non Formulary NICE therapeutic topic: Omega-3 fatty acid supplements
Omega-3-Acid Ethyl Esters 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Ondansetron 04.06 Formulary NICE Evidence Summary: Ondansetron for vomiting in children with gastroenteritis
Orlistat 04.05.01 Restricted Use NICE CG189: Obesity: identification, assessment and management
Osimertinib 08.02.04 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxyzyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Padeliporfin 08.01.05 Non Formulary NICE TA546: Padeliporfin for untreated localised prostate cancer
Palbociclib 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Non Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patisiran 09.08.01 Formulary NICE HST10: Patisiran for treating hereditary transthyretin amyloidosis
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Pegaspargase 08.01 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Pegloticase 10.01.04 Non Formulary NICE TA291: Pegloticase for treating severe debilitating chronic tophaceous gout
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA570: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pentosan polysulfate sodium 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Pentoxifylline 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pimecrolimus 1% cream 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pioglitazone 06.01.02.03 Formulary NICE NG49: Non-alcoholic fatty liver disease (NAFLD): assessment and management
Pirfenidone 03.11 Formulary NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Formulary NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for myeloma
Ponatinib 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Pramipexole 04.09.01 Formulary NICE NG71: Parkinson’s disease in adults
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Quetiapine 04.02.01 Formulary NICE Evidence summary: Quetiapine for generalised anxiety disorder
Quetiapine XL 04.02.01 Formulary NICE Evidence summary: Quetiapine for generalised anxiety disorder
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Radium-223 dichloride 08.03.04.02 Formulary NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene 08.03.04.01 Formulary NICE CG164: Familial breast cancer
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ramucirumab 08.01.05 Non Formulary NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ramucirumab 08.01.05 Non Formulary NICE TA609: Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
ReCell Spray on Skin system A5.04 Non Formulary NICE MTG21: ReCell Spray‑On Skin system for burn injury
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
RESPeRATE® device 16.01 Non Formulary NICE CG127: Hypertension in adults: diagnosis and management
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribociclib 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Rifaximin 05.01.07 Non Formulary NICE evidence summary: Rifaximin for pouchitis
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risankizumab 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 08.02.03 Formulary NICE Evidence Summary: Rituximab for ITP
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivastigmine 04.11 Formulary NICE NG71: Parkinson’s disease in adults
Rivastigmine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Rivastigmine 04.11 Formulary NICE NG71: Parkinson’s disease in adults
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib 08.02.04 Formulary NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan▼ 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA350: Plaque Psoriasis
Secukinumab 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Sildenafil 02.05.01 Non Formulary NICE Evidence summary: Sildenafil for digital ulcers
Sildenafil 02.05.01 Formulary NICE Evidence summary: Pulmonary hypertension in neonates - Sildenafil
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sirolimus 08.02.02 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Sirolimus 08.02.02 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Sodium Zirconium Cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir - Velpatasvir - Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Sofosbuvir and Velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Strimvelis 16.01 Formulary NICE HST7: Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus Ointment 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Restricted Use NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tamoxifen 08.03.04.01 Formulary NICE CG164: Familial Breast Cancer
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temsirolimus 08.01.05 Non Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel 08.02.04 Formulary NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.02.04 Formulary NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib citrate 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib citrate 10.01.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib citrate 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Tranexamic Acid 02.11 Formulary NICE Evidence summary: Tranexamic acid for significant haemorrhage following trauma
Tranexamic Acid 02.11 Formulary CKS Review of Evidence: Drugs to treat menorrhagia
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine–tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ulipristal 06.07.02 Non Formulary NICE NG88: Heavy menstrual bleeding: assessment and management
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Vandetanib 08.01.05 Non Formulary NICE TA550: Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Voretigene Neparvovec 16.01 Formulary HST11: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations
Vortioxetine 04.03.04 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zoledronic Acid 5mg 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Oxfordshire Clinical Commissioning Group